UNSPSC 51362503: Eszopiclone

This classification denotes a sedative and hypnotic with the molecular formula C17H17ClN6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UZX80K71OE, chemically known as 4-methyl-1-piperazinecarboxylic acid ester with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5h-pyrrolo(3,4-b)pyrazin-5-one but generally known as eszopiclone, which bears US NIH Compound Identifier 5735. European Medicines Agency schedules Eszopiclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21373.

UNSPSC 51362503 Eszopiclone is a Commodity code, but recent state and local procurement activity tagged to this code does not reflect eszopiclone procurement. Instead, the recorded opportunities target naloxone distribution systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply arrangements — none of which align with the specific pharmaceutical product (eszopiclone, a sedative-hypnotic medication) the code nominates. The mismatch suggests either miscoding by issuing bodies or a broader interpretation of pharmaceutical procurement under this code that diverges sharply from the code's intended scope. State and local governments buying under this code appear to include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances; the mix reflects both direct procurement by local jurisdictions and aggregated purchasing vehicles serving multiple state and local members.

Recent activity centers on Florida and the multistate cooperative vehicle. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program aimed at bypassing traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. The MMCAP RFP requires vendors to certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of the three authorized wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence, with a two-year initial contract term and potential extensions at MMCAP's sole discretion.